Caribou Biosciences to Discontinue CAR-T Programs, Opens Strategic Review

Caribou Biosciences (CRBU ) announced on October 6, 2026 that it is exploring strategic alternatives to maximize stockholder value and plans to discontinue further development of its two allogeneic CAR-T cell therapy programs, vispa-cel for relapsed or refractory B cell non-Hodgkin lymphoma and CB-011 for relapsed or refractory multiple myeloma, while implementing a substantial workforce reduction expected to be mostly complete in the fourth quarter of 2026. The Berkeley, California-based clinical-stage CRISPR genome-editing company held cash, cash equivalents, and marketable securities of $113.8 million as of June 30, 2026.

The company’s Board of Directors approved initiating the evaluation process on October 2, 2026, according to a Form 8-K filed with the U.S. Securities and Exchange Commission on October 6. The Board established a Transaction Committee to explore, evaluate, and make recommendations on strategic alternatives, including a merger, acquisition, business combination, or other strategic transactions involving the company and/or its assets. Wedbush Securities Inc. has been engaged as the company’s exclusive financial advisor. Caribou has not set a timeline for completing the review and does not intend to provide further updates unless the Board approves a course of action, the review process concludes, or disclosure is otherwise determined to be appropriate. The company stated it cannot commit that the process will result in any transaction.

The Board took the actions in view of the current financing environment for allogeneic CAR-T cell therapies, which the filing states has made it increasingly challenging to secure the capital necessary to responsibly advance the programs. “This is an extraordinarily difficult decision, particularly because it is in no way a reflection of our belief that vispa-cel and CB-011 have the potential to benefit patients,” said Rachel Haurwitz, PhD, president and chief executive officer of Caribou. She stated that vispa-cel is pivotal trial-ready, with FDA alignment already reached on the phase 3 clinical trial design.

Restructuring Costs and Workforce Reduction

Caribou estimates it will incur total restructuring expenses of approximately $15 million to $19 million, a substantial portion of which it expects to recognize during the fourth quarter of 2026, according to the 8-K. The anticipated expenses primarily include one-time severance payments, continued healthcare coverage, and related costs of approximately $10 million to $11 million, plus future costs of $5 million to $8 million to wind down the ANTLER phase 1 trial of vispa-cel and the CaMMouflage phase 1 trial of CB-011. The company stated it is unable at this time to make a good faith estimate of other charges, including any related to its facility lease, contract terminations, or asset impairments, and will file an amendment to the 8-K within four business days after making such a determination.

The workforce reduction is anticipated to occur in phases, with the majority of affected employees expected to depart in the fourth quarter of 2026. A limited number of employees are expected to remain through completion of the strategic process to support transaction execution and business wind-down activities. Caribou also intends to terminate applicable contracts, resolve various intellectual property licensing arrangements, and seek ways to sublease its facilities or terminate facility leases. An ongoing long-term follow-up study for patients previously treated with any investigational Caribou product candidate continues.

Separately, the employment of Chief Financial Officer Sriram Ryali will terminate on the date the company executes a binding definitive agreement for a strategic alternative, and that termination would be treated as a termination without cause under his employment agreement dated January 2, 2025, the filing states.

Discontinued CAR-T Programs

Vispa-cel (vispacabtagene regedleucel, formerly CB-010) is an allogeneic anti-CD19 CAR-T cell therapy evaluated in patients with relapsed or refractory B cell non-Hodgkin lymphoma. According to Caribou, it is the first allogeneic CAR-T cell therapy in the clinic with a PD-1 knockout, a genome-editing strategy designed to enhance CAR-T cell activity by limiting premature CAR-T cell exhaustion. The FDA granted vispa-cel Regenerative Medicine Advanced Therapy (RMAT), Fast Track, and Orphan Drug designations for B-NHL.

In long-term follow-up data from the ANTLER phase 1 trial presented in June 2026, 27 second-line large B cell lymphoma patients who received a single dose of 80 million optimized vispa-cel cells, defined as cells from a donor younger than 30 with at least two matched human leukocyte antigen alleles, showed an 82% overall response rate, a 67% complete response rate, and a 17.1-month median progression-free survival, as reported in the company’s second-quarter 2026 results release. Caribou had previously reached FDA alignment on its planned ANTLER-3 pivotal phase 3 trial, designed as a randomized, controlled study enrolling approximately 250 CD19-naive second-line LBCL patients not eligible for transplant and not candidates for autologous CAR-T cell therapy based on access challenges or medical criteria.

CB-011 is an allogeneic anti-BCMA CAR-T cell therapy evaluated in relapsed or refractory multiple myeloma, which the company describes as the first allogeneic CAR-T cell therapy in the clinic engineered to enable activity through an immune cloaking strategy combining a B2M knockout and insertion of a B2M–HLA-E-peptide fusion protein to blunt immune-mediated rejection. The FDA granted CB-011 RMAT, Fast Track, and Orphan Drug designations. In CaMMouflage phase 1 dose escalation data, 12 BCMA-naive patients treated at the 450 million cell recommended dose for expansion after lymphodepletion showed a 92% overall response rate, an 83% complete response or stringent complete response rate, and 91% minimal residual disease negativity in 10 of 11 evaluable patients, the company reported.

Caribou reported licensing and other third-party revenue of $1.5 million for the second quarter of 2026, research and development expenses of $18.9 million, general and administrative expenses of $7.9 million, and a GAAP net loss of $24.3 million, or $0.24 per share. Cash, cash equivalents, and marketable securities stood at $113.8 million as of June 30, 2026, compared with $142.8 million as of December 31, 2025. As of its August 13, 2026 results announcement, the company had expected its cash to fund its then-current operating plan, including CB-011 dose expansion and certain ANTLER-3 start-up activities, to the end of 2027, and stated it was exploring multiple options to fully fund the planned ANTLER-3 trial.